Neuroprotection in glaucoma

Tamm, Ernst R.; Grehn, Franz; Pfeiffer, Norbert

doi:10.1007/s00441-013-1672-0

Cited by 9 publications

(6 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The underlying mechanisms remain unclear. Many molecules have been shown to be neuroprotective in various animal models such as optic nerve (ON) transection, crush, or ocular hypertension (Tamm et al, 2013). …”

Section: Introductionmentioning

confidence: 99%

Neuroprotective effects of C3 exoenzyme in excitotoxic retinopathy

Wang

Yang

et al. 2014

Experimental Eye Research

View full text Add to dashboard Cite

The purpose of this study is to evaluate the neuroprotective effects of C3 exoenzyme (C3) on N-methyl-D-aspartate (NMDA)-induced retinopathy in rats. C3 was expressed in Escherichia. coli and purified by affinity chromatography. Immunofluorescence was performed in NIH 3T3 cells treated with C3 to verify the cellular uptake of the protein. NMDA was injected intravitreally into rat eyes with or without C3. At various time points after injection, eyes were enucleated. Hematoxylin/eosin staining was performed on retina cross-sections for morphological analysis. Survival and apoptosis of cells in the ganglion cell layer (GCL) were assessed by cresyl violet staining and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) on retina flat-mounts. RhoA levels in retina cells were evaluated by Western blot to detect C3 uptake in vivo. The cellular uptake of C3 was verified by immunofluorescence. Damage including a decrease in inner plexiform layer (IPL) thickness and reduction of cell density in the GCL, corresponding to apoptosis of neurons, was induced by intravitreal injection of NMDA. Protection against this damage was observed following co-injection of C3 and NMDA. RhoA ADP-ribosylation induced by C3 was confirmed by Western blot. Our results suggest that C3 exerts neuroprotective effects against excitotoxic damage induced by NMDA.

show abstract

Section: Introductionmentioning

confidence: 99%

Neuroprotective effects of C3 exoenzyme in excitotoxic retinopathy

Wang

Yang

et al. 2014

Experimental Eye Research

View full text Add to dashboard Cite

show abstract

“…Each patient was subject of a full ophthalmologic examination and topical and systemic treatment to lower elevated IOP (including YAG iridotomy, in some cases also iridectomy) and to relieve symptoms after diagnosis of AACG at the Department of Ophthalmology, University Medical Center Mainz (study participant characteristics: Table 1). Examination and blood collection time points were directly after study inclusion (0 weeks, time point 1: T1) and after 2 weeks AE3 days (time point 2: T2), 4 weeks AE7 days (time point 3: T3) and 12 (7063)). Before onset of the study, written informed consent was taken from all study participants.…”

Section: Methods Patientsmentioning

confidence: 99%

“…Most defects in the visual field of patients are detected when almost 20–40% of RGC are irreversibly lost . Diagnosis in clinical routine can be challenging, and an adequate, individual therapy of the disease is essential to prevent possible blindness . A significant risk factor for POAG is an elevated IOP.…”

Section: Introductionmentioning

confidence: 99%

“…10 Diagnosis in clinical routine can be challenging, and an adequate, individual therapy of the disease is essential to prevent possible blindness. 11,12 A significant risk factor for POAG is an elevated IOP. At the moment, it is the only modifiable target to slow glaucomatous damage, but detailed mechanisms of occurring RGC loss remain unclear.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Course of serum autoantibodies in patients after acute angle‐closure glaucoma attack

Lorenz

Beck

Keilani

et al. 2017

Clinical Exper Ophthalmology

Self Cite

View full text Add to dashboard Cite

With this autoantibodies profiling approach, we were able to detect autoimmune reactivities in sera of patients without former indication for glaucomatous damage after rise of IOP due to AACG attack. After further validation in subsequent studies, this autoantibodies could give further insights into the pathogenesis of glaucoma and could possibly help to understand the effect of IOP on glaucomatous optic neuropathy.

show abstract

“…The development of neuroprotective agents has been a strong area of focus over the last decade, as summarized by recent review articles. 49,50 Particular attention has been drawn to the role of neurotrophic molecules that promote neuron survival and differentiation, cell-based therapies to replace RGCs, the role of immune modulation, and vascular factors such as ocular blood flow.…”

Section: Neuroprotectionmentioning

confidence: 99%

One Year of Glaucoma Research in Review

Kim¹,

Demetriades²,

Radcliffe³

2014

Asia-Pacific Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose The objective of this study was to provide the practicing clinical ophthalmologist with an update of pertinent glaucoma literature published from 2012 to 2013. Design Literature review. Methods The authors conducted a 1-year (July 1, 2012, to September 30, 2013) English-language glaucoma literature search on PubMed using the following terms: glaucoma, automated perimetry, optic nerve imaging, optical coherence tomography, glaucoma structure and function, intraocular pressure, central corneal thickness, glaucoma medical therapy, neuroprotection, glaucoma laser treatment, secondary glaucoma, glaucoma surgery, and miscellaneous topics in glaucoma. Results Of 2659 articles on glaucoma published during our time frame, this review selected original and review articles that reflect novel aspects and updates in the field of glaucoma, while excluding letters to the editor, unpublished works, and abstracts. Preference was given to human research. Conclusions This review focuses on literature that is applicable to ophthalmologists in practice and also highlights studies that may enhance the diagnosis and management of glaucoma.

show abstract

Neuroprotection in glaucoma

Cited by 9 publications

References 22 publications

Neuroprotective effects of C3 exoenzyme in excitotoxic retinopathy

Neuroprotective effects of C3 exoenzyme in excitotoxic retinopathy

Course of serum autoantibodies in patients after acute angle‐closure glaucoma attack

One Year of Glaucoma Research in Review

Contact Info

Product

Resources

About